The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.
Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA’s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI’s market survey, the annual sales value of entecavir in China rose from CNY 30 million in 2006 to CNY 1.207 billion in 2014 and CAGR during this period reached up to 55%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 60% in 2014 for sales value and over 50% for sales volume.
Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug’s entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.
Readers can get at least the following information from this report:
-market size of entecavir in China
-competitive landscape of entecavir in Chinese market
-price of entecavir made by different manufacturers in China
-market outlook of entecavir in China
The author suggests the following groups of people purchase this report:
-manufacturers of anti-HBV drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service